Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for...

Full description

Bibliographic Details
Published in:Journal for ImmunoTherapy of Cancer
Main Authors: Rajeev Sharma, Laura C Cappelli, Michelle Turner, Julie R Brahmer, Jarushka Naidoo, Paolo Antonio Ascierto, Igor Puzanov, Hamzah Abu-Sbeih, Jeffrey A Sosman, Marc S Ernstoff, Jill Brufsky, Mario E Lacouture, Douglas B Johnson, Lamya Hamad, Miguel-Angel Perales, Eric Hansen, David E Gerber, Frank B Cortazar, Gregory A Masters, Michele Nanni, Satish P Shanbhag, Dimitra Skondra
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Online Access:https://jitc.bmj.com/content/9/6/e002435.full
Description
Summary:Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.
ISSN:2051-1426

Similar Items